68 related articles for article (PubMed ID: 21344614)
1. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
Donnan JR; Ungar WJ; Mathews M; Hancock-Howard RL; Rahman P
Pediatr Blood Cancer; 2011 Aug; 57(2):231-9. PubMed ID: 21344614
[TBL] [Abstract][Full Text] [Related]
2. Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial.
Zhou Y; Wang L; Sun LR; Zhang L; Wang HM; Liu XT; Yang F; Wu KL; Liang YL; Zhao BB; Zhuang Y; Fu JQ; Song C; Li Y; Wang LZ; Xu HJ; Gu Y; van den Anker J; Ju XL; Zhu XF; Zhao W
Clin Pharmacol Ther; 2024 Feb; 115(2):213-220. PubMed ID: 37753808
[TBL] [Abstract][Full Text] [Related]
3. 6-Mercaptopurine-Associated Sinusoidal Obstructive Syndrome During Interim Maintenance I: A Case Report.
Voelz K; Miller G; Lee-Miller C
J Pediatr Hematol Oncol; 2024 May; ():. PubMed ID: 38775421
[TBL] [Abstract][Full Text] [Related]
4. Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing.
Phillips KA; Pletcher MJ; Ladabaum U
Technol Health Care; 2015; 23(3):373-9. PubMed ID: 25669213
[No Abstract] [Full Text] [Related]
5. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.
Thompson AJ; Newman WG; Elliott RA; Roberts SA; Tricker K; Payne K
Value Health; 2014; 17(1):22-33. PubMed ID: 24438714
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles.
Zarca K; Chansavang A; Loriot MA; Durand-Zaleski I; Pallet N
Pharmacogenet Genomics; 2020 Oct; 30(8):175-183. PubMed ID: 32433339
[TBL] [Abstract][Full Text] [Related]
7. Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis.
Zarca K; Durand-Zaleski I; Loriot MA; Chatellier G; Pallet N
Mol Diagn Ther; 2019 Jun; 23(3):429-438. PubMed ID: 30963516
[TBL] [Abstract][Full Text] [Related]
8. Impact on CDC Guideline Compliance After Incorporating Pharmacy in a Pneumococcal Vaccination Screening Process.
Pickren E; Crane B
Hosp Pharm; 2016 Dec; 51(11):894-900. PubMed ID: 28057948
[No Abstract] [Full Text] [Related]
9. Preemptive
Valdez-Acosta S; Zubiaur P; Casado MA; Novalbos J; Casajús A; Campodónico D; Oyagüez I; Abad-Santos F
J Pers Med; 2023 Jul; 13(8):. PubMed ID: 37623459
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.
Morris SA; Alsaidi AT; Verbyla A; Cruz A; Macfarlane C; Bauer J; Patel JN
Clin Pharmacol Ther; 2022 Dec; 112(6):1318-1328. PubMed ID: 36149409
[TBL] [Abstract][Full Text] [Related]
11. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
Vu M; Degeling K; Thompson ER; Blombery P; Westerman D; IJzerman MJ
Eur J Haematol; 2022 Jun; 108(6):469-485. PubMed ID: 35158410
[TBL] [Abstract][Full Text] [Related]
12. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.
Mhandire DZ; Goey AKL
Mol Diagn Ther; 2022 Mar; 26(2):137-151. PubMed ID: 35113367
[TBL] [Abstract][Full Text] [Related]
13. Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes.
Hutchcraft ML; Lin N; Zhang S; Sears C; Zacholski K; Belcher EA; Durbin EB; Villano JL; Cavnar MJ; Arnold SM; Ueland FR; Kolesar JM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572750
[TBL] [Abstract][Full Text] [Related]
14. Utility-Based Multicriteria Model for Screening Patients under the COVID-19 Pandemic.
Roselli LRP; Frej EA; Ferreira RJP; Alberti AR; de Almeida AT
Comput Math Methods Med; 2020; 2020():9391251. PubMed ID: 32908584
[TBL] [Abstract][Full Text] [Related]
15. Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?
Luber RP; Honap S; Cunningham G; Irving PM
Front Med (Lausanne); 2019; 6():279. PubMed ID: 31850357
[TBL] [Abstract][Full Text] [Related]
16. Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.
Faruque F; Noh H; Hussain A; Neuberger E; Onukwugha E
J Manag Care Spec Pharm; 2019 Feb; 25(2):260-271. PubMed ID: 30698084
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic testing in oncology: a Brazilian perspective.
Suarez-Kurtz G
Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e565s. PubMed ID: 30328952
[TBL] [Abstract][Full Text] [Related]
18. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Verbelen M; Weale ME; Lewis CM
Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
[TBL] [Abstract][Full Text] [Related]
20. Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature.
Cesuroglu T; Syurina E; Feron F; Krumeich A
BMJ Open; 2016 Jul; 6(7):e010243. PubMed ID: 27412099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
